ANI Pharmaceuticals, Inc. (ANIP)
81.10
-1.64
(-1.98%)
USD |
NASDAQ |
Dec 05, 11:04
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.821B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 45.52% |
| Valuation | |
| PE Ratio | 49.74 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.983 |
| Price to Book Value | 3.601 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.249 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 72.96% |
Profile
| ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN. |
| URL | http://www.anipharmaceuticals.com |
| Investor Relations URL | https://investor.anipharmaceuticals.com |
| HQ State/Province | Minnesota |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 27, 2026 (est.) |
| Last Earnings Release | Nov. 07, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN. |
| URL | http://www.anipharmaceuticals.com |
| Investor Relations URL | https://investor.anipharmaceuticals.com |
| HQ State/Province | Minnesota |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 27, 2026 (est.) |
| Last Earnings Release | Nov. 07, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |